Real-world survival ‘inferior’ to trials for ERBB2-positive metastatic cancer
Canadian breast cancer data differs from results seen in the CLEOPATRA and EMILIA trials, researchers report
Patient survival in the real-world is inferior to that seen in clinical trials of pertuzumab and trastuzumab emtansine for ERBB2-positive metastatic breast cancer, a study shows.
The cause is likely due to differences in patient characteristics and previous therapy, the Canadian researchers say.
The investigators accessed electronic health records of women in Ontario with stage IV ERBB2-positive metastatic breast cancer receiving either first-line treatment with pertuzumab from 2013-2017, or second-line trastuzumab emtansine from 2014-2017.
The primary outcome was overall survival (OS).
